We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Codon Devices Signs Distribution Agreement with Open Biosystems
News

Codon Devices Signs Distribution Agreement with Open Biosystems

Codon Devices Signs Distribution Agreement with Open Biosystems
News

Codon Devices Signs Distribution Agreement with Open Biosystems

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Codon Devices Signs Distribution Agreement with Open Biosystems"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Codon Devices, Inc., the Constructive Biology Company™, has announced that it has entered into an agreement in which Open Biosystems will distribute Codon Devices’ gene synthesis offering in North America.

Central to its vision of Constructive Biology™, Codon Devices is driving wide-spread adoption of synthetic genes. To date, the Company has maintained a minimum order threshold and thus access to its industrial-scale BioFAB™ platform has been restricted to researchers with large-scale requirements.

Under the terms of the agreement, Open Biosystems will sell and distribute Codon Devices’ gene synthesis offering to researchers with needs that fall below Codon’s minimum order threshold. The partnership will enable a wide range of new customers to utilize gene synthesis in their research.

“Through aggressive investments in its BioFAB™ platform, Codon Devices has moved quickly to industrialize synthetic biology and become a world leader in gene synthesis,” said Brian Pollock, Chief Executive Officer, Open Biosystems. “We are delighted to provide our customers with a new product offering that is clearly revolutionizing how life science research is conducted.”

Advertisement